AMGEN 757

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757
in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Male and female subjects (> 18 years of age) with histologically or cytologically confirmed relapsed/refractory SCLC who progressed or recurred following 1 platinum-based regimen and at least 1 other prior line of therapy
Note:

[1] re-treatment with a platinum-based regimen is considered a second line of therapy;

[2] platinum-based regimen followed by checkpoint inhibitor/anti-programmed death ligand 1 [PD-L1] as maintenance therapy is considered 1 line of therapy;

[3] in countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with PD-L1 inhibitor, it is required that subjects to have failed PD-L1 inhibitor as part of their first line systemic treatment or not have access to).